Songli Zhu

Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa — South Africa

Biochemistry, Genetics and Molecular Biology · Life Sciences

11h-index301citations34works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

DNA Repair Mechanisms(10), Cancer Genomics and Diagnostics(8), Microtubule and mitosis dynamics(6), Mitochondrial Function and Pathology(3), Cancer Cells and Metastasis(3)

Publications34 total

A systems approach identifies MERTK as a therapeutic vulnerability in ZFTA-RELA-driven ependymomas
Proceedings of the National Academy of Sciences·2026Open Access
Subtype-Specific Dependencies and Drug Vulnerabilities Enable Precision Therapeutics in Head and Neck Cancer
2025Open Access
BIOM-95. A RAPID AI-DRIVEN PLATFORM FOR PERSONALIZED DRUG RESPONSES IN RECURRENT BRAIN TUMORS
Neuro-Oncology·2025Open Access
Drug screening in 3D microtumors reveals DDR1/2-MAPK12-GLI1 as a vulnerability in cancer-associated fibroblasts
Cell Reports Medicine·2025· 2 citedOpen Access
DNAJ-PKAc fusion heightens PLK1 inhibitor sensitivity in fibrolamellar carcinoma
Gut·2025· 4 citedOpen Access
Correction: DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming
Cancer Discovery·2025Open Access
γ-tubulin mediates DNA double-strand break repair
Journal of Cell Science·2025· 2 citedOpen Access
Supplementary Figures S1-S8 from DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming
2025Open Access
Supplementary Tables S1-S7 from DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming
2025Open Access
Contents of Supplementary Tables from DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming
2025Open Access
A Systems approach identifies MERTK as a therapeutic vulnerability in ZFTA-RELA-driven ependymomas
2025· 1 citedOpen Access
Supplementary Tables S1-S7 from DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming
2025Open Access
Contents of Supplementary Tables from DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming
2025Open Access
Data from DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming
2025· 2 citedOpen Access
Supplementary Figures S1-S8 from DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming
2025Open Access
A phase 2 study of frontline pembrolizumab in follicular lymphoma
eJHaem·2024Open Access
Microfluidic Modulation of Microvasculature in Microdissected Tumors
2024· 1 citedOpen Access
DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming
Cancer Discovery·2024· 10 citedOpen Access
Microdissected tumor cuboids: a microscale cancer model for large-scale testing that retains a complex tumor microenvironment
2024· 4 citedOpen Access
Abstract 616: Integrating organotypic tissue slices and polypharmacology-based screening to map the toxicity landscape of kinase inhibitors
Cancer Research·2024
page 1 of 2Next →

Frequent Co-authors

Taranjit S. Gujral(19), Marina Chan(17), Joel Markus Vaz(12), Aimin Peng(9), Ilaria Gritti(9), Jinkai Wan(9), Giuseppe Tarantino(9), Tenna Holgersen Bryde(9), Vindhya Vijay(9), Ashwin V. Kammula(9), Prabhat Kattel(9), Meng‐Ju Wu(9), John D. Gordan(9), Krushna C. Patra(9), Vanessa S. Silveira(9), Robert T. Manguso(9), Marc N. Wein(9), Christopher J. Ott(9), Jun Qi(9), David Liu(9)